REG - Arecor Therapeutics - Arecor announces formulation study collaboration

Arecor TherapeuticsAnnouncement

01/11/2021 07:05

RNS Number : 8164Q
  
Arecor Therapeutics PLC
  
01 November 2021
  
 

Arecor Therapeutics plc
("Arecor" or the "Group")
 
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH

A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
 
Cambridge, UK, 1 November 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a leading global medical products company.
 
Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a differentiated, stable, liquid drug product, for intravenous administration in two concentrations, that is Ready-to-Administer ("RTA").  The new liquid formulation of the product supports safe medication practices and operational efficiency by eliminating the need for reconstitution.  The partner will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model to further develop and commercialise the product.
 
Sarah Howell, Chief Executive Officer of Arecor, said:  "We are very pleased to announce this new partnership today, our fourth in the past six months, showcasing our commercial strategy to drive growth through our portfolio of collaborations across leading pharmaceutical, medical products and biotech companies.  This collaboration further demonstrates the strength of our proprietary technology platform, Arestat™ in developing ready-to-administer (RTA) medicines, which are becoming increasingly important to enable fast, safe and effective treatment of patients."
 
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)
-ENDS-
 
For more information, please contact:



Arecor Therapeutics plc


www.arecor.com




Dr Sarah Howell, Chief Executive Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com




 


 




Susan Lowther, Chief Financial Officer


Tel: +44 (0) 1223 426060
Email: info@arecor.com




 


 




Mo Noonan, Communications


Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com




 


 




Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)


Tel: +44 (0) 20 7886 2500
 




 


 




Consilium Strategic Communications


 




Chris Gardner, David Daley, Angela Gray


Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com



 
Notes to Editors
 
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.  
 
For further details please see our website, www.arecor.com
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCEAPEFDDAFFFA